ArticleFrontiers in endocrinology2025
Urinary lipid metabolites and progression of kidney disease in individuals with type 2 diabetes.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A substantial proportion of individuals with type 2 diabetes (T2D) experience a fast decline (FD) in kidney function, a high-risk phenotype not reliably identified by current clinical markers. This study aimed to evaluate the potential of urinary lipid metabolites as novel predictors for the rapid progression of diabetic kidney disease (DKD). Methods: This investigation employed a dual-phase design comprising cross-sectional screening and longitudinal validation. In the initial phase, targeted lipidomic profiling of urine samples from 152 patients with T2D and DKD and 152 age- and sex-matched individuals with uncomplicated diabetes revealed distinct metabolite patterns. The subsequent validation phase utilized an independent cohort of 248 T2D patients, in which rapid kidney function decline was defined as the highest quartile of annual estimated glomerular filtration rate (eGFR) reduction. Feature selection was performed using machine learning algorithms (random forest and Boruta) to identify potential biomarkers from the differentially expressed metabolites. The prognostic value of these lipid markers for predicting future renal function decline was assessed against clinical variables using receiver operating characteristic (ROC) analysis. Results: The analysis of fasting spot urine specimens quantified 104 lipid metabolites out of 508 targeted species, with all concentrations normalized to urinary creatinine. The comparative analysis identified 21 lipid metabolites that were significantly upregulated in the DKD group. Feature selection algorithms isolated nine (Boruta) and eight (random forest) candidate biomarkers from this pool. During a median follow-up period of 33 months (IQR 17-47), 62 participants showing the most rapid eGFR decline were classified as the FD group. These individuals exhibited significantly elevated baseline levels of the identified lipid metabolites. The lipid panel demonstrated superior predictive performance for future kidney function decline compared with traditional clinical predictors, including baseline eGFR, hemoglobin A1c, and albuminuria. Conclusions: Our findings reveal a strong association between urinary lipid metabolites and DKD progression. Specifically, urinary lipid profiling shows promise as a non-invasive tool to identify T2D patients at a high risk for rapid kidney function decline, outperforming the current clinical standard of albuminuria and eGFR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.